D. Schallier
Vrije Universiteit Brussel
26 Papers
94 Citations
D. Schallier is an academic researcher from Vrije Universiteit Brussel. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 12, co-authored 26 publications.
Chat about Author
Papers
Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC).
Lore Decoster,D. Schallier,Hendrik Everaert,Koenraad Nieboer,Marc Meysman,Bart Neyns,J. De Mey,J. P. De Greve +7 more
TL;DR: A CR on 18FDG-PET following induction chemotherapy for locally advanced, unresectable NSCLC seems to be a more powerful prognostic marker for survival compared to PR on CT.
65
Tolerance of adjuvant letrozole outside of clinical trials.
Christel Fontaine,A Meulemans,Manon T. Huizing,Christine Collen,Leonard Kaufman,J. De Mey,Claire Bourgain,G Verfaillie,Jan Lamote,Robert Sacre,D. Schallier,Bart Neyns,Jan B. Vermorken,J. P. De Greve +13 more
TL;DR: Although adjUvant aromatase inhibitors have proven to be generally superior to tamoxifen in the adjuvant setting, it is important to focus attention on the tolerance during the adjuvant therapy and to balance this against the potential benefit in individual patients.
56
•Journal Article
Tyrosine kinase inhibitor-induced macrocytosis.
TL;DR: The data suggest pathways in addition to c-KIT and not common to both agents are involved in the TKI-induced macrocytosis, which was not confined to patients with RCC alone but also occurred in patients with BC.
24
•Journal Article
Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases
Bart Neyns,Yves Van Nieuwenhove,M. Aerts,Christel Fontaine,Joanna Vermeij,D. Schallier,Lore Decoster,Johan De Mey,Frederik Vandenbroucke,Anne Hoorens,Georges Delvaux,Jacques De Greve +11 more
TL;DR: HAI of oxaliplatin plus CI5-FU/LV is feasible and merits further evaluation.
24
•Journal Article
Docetaxel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC): an Observational Study in a Single Institution
TL;DR: Treatment with docetaxel was well-tolerated and only two patients were withdrawn for non-haematological toxicity during first- and further-line treatment, in line with the data from TAX 327.
16